Furthermore, the study finds that Oridonin combined with PD-L1 inhibitors alleviates immune suppression and increases the content of cytokines secreted by CD8+ T cells, thereby enhancing the antitumor effects of the tumor immune microenvironment. Here, CD274 is linked to neoplasm.